Pharmaceutical Compositions Of Fingolimod

Patent No. EP3027174 (titled "Pharmaceutical Compositions Of Fingolimod") was filed by Aizant Drug Research Solutions Private on Dec 10, 2013. The application was issued on Jul 24, 2019.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Company	Opposition Date	Representative
DF MP DORRIES FRANK MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBB	Apr 24, 2020	EDER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Sep 14, 2021
Communication to the parties concerning the termination of the opposition proceedings (opponent)
Sep 14, 2021
Communication to the parties concerning the termination of the opposition proceedings (proprietor)
Sep 9, 2021
Termination of the opposition proceedings with revocation of patent
Jun 2, 2021
(Electronic) Receipt
Jun 2, 2021
Advice of delivery
Jun 2, 2021
Advice of delivery
Jun 2, 2021
Letter accompanying subsequently filed items
May 31, 2021
Decision of the Opposition Division and instruction
May 31, 2021
Decision revoking the European patent
May 31, 2021
Grounds for the decision (Annex) - opposition
May 31, 2021
Internal form - Opposition/addressees
May 31, 2021
Means of redress
May 31, 2021
Transmittal of decision / summons - opposition
May 31, 2021
Transmittal of decision / summons - opposition
Jun 23, 2020
Communication of a notice of opposition and request to file observations
Jun 23, 2020
Notice of further oppositions to opponent(s)
May 14, 2020
Brief communication - Opposition proceedings
May 11, 2020
(Electronic) Receipt
May 11, 2020
Citation in opposition procedure - 001
May 11, 2020
Citation in opposition procedure - 002
May 11, 2020
Citation in opposition procedure - 003
May 11, 2020
Letter accompanying subsequently filed items
May 11, 2020
Letter regarding the opposition procedure (no time limit)
May 11, 2020
Request for documents
May 7, 2020
Communication of a notice of opposition - first information to patent proprietor
Apr 24, 2020
(Electronic) Receipt
Apr 24, 2020
Citation in opposition procedure - 004
Apr 24, 2020
Citation in opposition procedure - 005
Apr 24, 2020
Consolidated list of cited opposition documents
Apr 24, 2020
International publication (Pamphlet)
Apr 24, 2020
Notice of opposition
Apr 24, 2020
Notice of opposition
Aug 5, 2019
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Jun 27, 2019
Decision to grant a European patent
May 14, 2019
(Electronic) Receipt
May 14, 2019
Filing of the translations of the claims
May 14, 2019
French translation of claims
May 14, 2019
German translation of the claims
Jan 4, 2019
Bibliographic data of the European patent application
Jan 4, 2019
Communication about intention to grant a European patent
Jan 4, 2019
Intention to grant (signatures)
Jan 4, 2019
Text intended for grant (clean copy)
Jan 4, 2019
Text intended for grant (version for approval)
Dec 3, 2018
Examination started
Aug 24, 2018
Notification regarding date of start of examination with possibility to withdraw
Jan 24, 2018
Refund of fees
Nov 15, 2016
(Electronic) Receipt
Nov 15, 2016
Letter accompanying subsequently filed items
Nov 15, 2016
Statement of non-availability of priority search results
Nov 7, 2016
Invitation to file a copy of search results(priority)
Sep 26, 2016
(Electronic) Receipt
Sep 26, 2016
Amended claims filed after receipt of (European) search report
Sep 26, 2016
Amendments received before examination
Sep 26, 2016
Letter accompanying subsequently filed items
May 11, 2016
Notification on forthcoming publication of bibliographic data
Mar 17, 2016
Communication concerning correction of deficiencies in written opinion/amendment of application/payment of claims fee
Mar 15, 2016
Communication to designated inventor
Mar 15, 2016
Communication to designated inventor
Mar 15, 2016
Communication to designated inventor
Mar 15, 2016
Communication to designated inventor
Mar 15, 2016
Communication to designated inventor
Mar 15, 2016
Communication to designated inventor
Feb 26, 2016
(Electronic) Receipt
Feb 26, 2016
Request for entry into the European phase
Feb 16, 2016
Copy of the international preliminary report on patentability
Dec 9, 2015
Information on entry into European phase
Feb 24, 2015
Priority document (electronically transmitted)
Feb 5, 2015
Copy of the international search report
Feb 5, 2015
Published international application - A1
May 7, 2014
Notification relating to priority claim
Apr 14, 2014
Notification relating to declaration under Rule 4.17 PCT (copy for ISA/EP)
Apr 8, 2014
Notification of the recording of a change
Apr 8, 2014
Notification of the recording of a change
Apr 8, 2014
Notification of the recording of a change
Apr 8, 2014
Notification of the recording of a change
Apr 8, 2014
Notification of the recording of a change
Apr 8, 2014
Notification of the recording of a change
Apr 8, 2014
Written opinion of the ISA, boxes No. I to VIII
Apr 8, 2014
Written opinion of the ISA, cover sheet
Apr 8, 2014
Written opinion of the ISA, supplemental box
Jan 23, 2014
Abstract
Jan 23, 2014
Claims
Jan 23, 2014
Description
Jan 23, 2014
Submission concerning representation

EP3027174

AIZANT DRUG RESEARCH SOLUTIONS PRIVATE

Application Number: EP13826764A
Filing Date: Dec 10, 2013
Status: Revoked; Sep 10, 2021
Publication Date: Jul 24, 2019
External Links: Slate, Register , Google Patents

IP Verse

Pharmaceutical Compositions Of Fingolimod

Patent Summary

Patent Family

Patent Oppositions

Dossier Documents

EP3027174